Drugs / Anti-CD33 CAR T cells
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05672147 | Dec 2023 → Sep 2028 expected | acute myeloid leukemia | City of Hope Medical Center | Recruiting | No outcome recorded |
| Phase 1 | NCT05445765 | Jul 2022 → Jun 2024 | acute myeloid leukemia | iCell Gene Therapeutics | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Anti-CD33 CAR T-cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05672147 ↗ |
| Modality | Cell therapy | “anti-CD33 CAR T cells will be transduced with a lentiviral vector to express anti-CD33 CARs” NCT05445765 ↗ |
| Route | Intravenous | “by IV injection” NCT05445765 ↗ |
| Target | CD33 | “CD33 is a potential good target by CAR T cells.” NCT05445765 ↗ |